Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $17.1K | $13.4K | $90.0K | $306K | $775K | $1.23M | $1.73M |
| Revenue growth | — | — | — | — | -21.4% | 570.3% | 240.3% | 153.0% | 59.1% | 40.0% |
| Operating income | -$12.4M | -$14.7M | -$17.9M | -$16.0M | -$21.2M | -$28.3M | -$31.8M | -$36.0M | -$27.0M | -$21.7M |
| Operating margin | — | — | — | -93840.2% | -158176.2% | -31469.0% | -10372.4% | -4641.8% | -2190.9% | -1258.5% |
| Net income | -$11.9M | -$14.8M | -$18.0M | -$16.1M | -$20.4M | -$27.0M | -$30.6M | -$35.7M | -$27.0M | -$23.4M |
| Net margin | — | — | — | -94168.5% | -151859.6% | -29977.0% | -9986.7% | -4601.7% | -2186.3% | -1352.2% |
| EPS (diluted) | -$0.52 | -$0.56 | -$0.57 | -$0.41 | -$0.45 | -$0.51 | — | -$0.50 | -$0.31 | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.86M | -$12.2M | -$14.7M | -$12.7M | -$16.5M | -$20.9M | -$15.3M | -$18.1M | -$25.9M | -$19.7M |
| Capital expenditures | $415K | $1.43M | -$302K | $511K | $1.94M | $974K | $1.57M | $1.08M | $277K | $89.6K |
| Free cash flow | -$9.28M | -$13.6M | -$14.4M | -$13.3M | -$18.4M | -$21.8M | -$16.8M | -$19.1M | -$26.2M | -$19.8M |
| Share buybacks | — | — | — | — | — | — | $0.00 | $31.8K | $0.00 | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $21.7M | $10.1M | $13.4M | $17.0M | $19.4M | $20.6M | $10.9M | $20.7M | $3.26M | $1.12M |
| Total assets | $24.7M | $14.6M | $17.5M | $21.3M | $26.2M | $27.5M | $18.3M | $28.0M | $9.40M | $6.90M |
| Total liabilities | $3.56M | $4.67M | $5.35M | $7.09M | $9.86M | $9.77M | $21.4M | $36.7M | $35.5M | $42.5M |
| Long-term debt | $432K | $1.31M | $1.98M | $2.20M | $2.61M | $2.27M | $2.78M | $3.62M | $3.95M | $5.82M |
| Shareholders' equity | $21.2M | $9.96M | $12.1M | $14.2M | $16.3M | $17.7M | -$2.57M | -$7.80M | -$24.9M | -$34.2M |
| Retained earnings | -$40.9M | -$55.7M | -$73.7M | -$89.8M | -$110M | -$137M | -$167M | -$203M | -$230M | -$253M |
| Shares (wtd avg diluted) | 26.1M | 26.5M | 35.3M | 41.1M | 48.6M | 53.8M | 57.9M | 71.2M | 86.5M | 107M |
Every figure is extracted from VOLITIONRX LTD’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.